Meeting Materials

Abstract: Introduction: Digital therapeutics (DTx) are a new treatment class for major depressive disorder (MDD). This randomized controlled trial evaluated the effectiveness and safety of a novel DTx for MDD as an adjunct to antidepressant treatment (ADT) monotherapy (NCT04770285).

A variety of multimodal treatments that can address the spectrum of MDD symptom domains and ongoing management challenges, including residual symptoms and treatment-emergent adverse effects (TEAEs) have emerged that may address unmet needs in MDD pharmacotherapy.

Abstract: Background: Caregivers play an important role in the lives of people with schizophrenia. This analysis aimed to understand the caregivers’ role and gain their perspective toward using long-acting injectable antipsychotics (LAI).

Abstract: Background: For patients with schizophrenia, long-acting injectable (LAI) antipsychotics can reduce relapse and hospitalization rates and improve adherence versus oral antipsychotics.

Abstract: Introduction: AXS-05 (dextromethorphan-bupropion; Auvelity) is a novel, oral, N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist approved for treating major depressive disorder (MDD) in adults.

Abstract: Parkinson's Disease (PD) psychosis poses major treatment challenges due to the delicate balance required between managing motor deficits and psychotic symptoms. Treating PD associated psychosis is complicated due to the etiology of the disease.

Abstract: Introduction: People with major depressive disorder (MDD) have impaired neuroplasticity. Antidepressant treatment and some nonpharmacological interventions can lead to changes in neuroplasticity that improve MDD symptoms.

Abstract: BACKGROUND: To generate real-world evidence of esketamine effectiveness for treatment resistant depression (TRD), this study assessed change in depressive symptoms after esketamine initiation in a large psychiatric practice based on Patient Health Questionnaire (PHQ-9) scores.

Abstract: Objective: Long-acting injectables (LAIs) may provide an advantage over daily oral antipsychotics (OAPs), but little real-world evidence exists in the Medicare population, which includes about half of US patients with schizophrenia.

Abstract: Introduction: Cognitive impairments associated with schizophrenia are burdensome and detrimental to everyday life. The Schizophrenia Cognition Rating Scale (SCoRS) is a 20-item interview-based assessment requiring input from patients, caregivers, or clinicians.

Abstract: Objective: A prior integrated patient-level analysis revealed a significant benefit of implementing paliperidone palmitate (PP) versus oral antipsychotics (OAPs) earlier in the course of schizophrenia.

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor for the treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)–related chorea.

Abstract: Rationale

Abstract: This research analyzes the outcomes of a federal training grant first awarded in 2017 by the Health Resources and Services Administration (HRSA) to address the shortage of behavioral health providers in the U.S.

Abstract: Introduction: A patient-digital therapeutic (DTx) bond (digital working alliance [DWA]) may be important for DTx success.

Abstract: Background: Individuals with major depressive disorder (MDD) with loss of interest and reduced activity respond poorly to serotonergic antidepressants.

Abstract: Background: Psychiatrists’ views on schizophrenia treatment goals and use of long-acting injectable antipsychotics (LAIs) vary widely.

Abstract: Introduction: Currently, no FDA-approved pharmacological treatments satisfactorily address experiential negative symptoms (ENS) of schizophrenia. CT-155 is a prescription digital therapeutic under investigation for the treatment of ENS.

Abstract: Background: The combination of olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. In real-world settings, OLZ/SAM treatment may be associated with healthcare resource utilization (HCRU) reductions.

Abstract: Background: Benztropine may be prescribed off-label to patients with tardive dyskinesia (TD) to provide symptom relief; however, per benztropine prescribing information, it may aggravate TD symptoms.

Abstract: Background

Abstract: Background: Patient-reported outcomes (PROs) are important for assessing disease burden. Specific measures characterizing the multidimensional impact of tardive dyskinesia (TD) are lacking.

Abstract: Background: Despite the prevalence of major depressive disorder (MDD), little is known about the burden of anhedonia, a core MDD symptom associated with MDD severity, functional impairment, and poor prognosis.

Abstract: Nurse burnout continues to be a significant challenge in healthcare settings, impacting both the well-being of nurses and the quality of patient care.

Abstract: Background: The IMPACT-TD Patient Reported Outcome (IMPACT-TD PRO) scale is a newly developed patient questionnaire to assess the multidimensional impact of tardive dyskinesia (TD) on the patients’ quality of life.

Abstract: A 57-year-old female patient with a known history of left frontotemporal meningioma presented to the emergency room with visual and auditory hallucinations and hyper-religiosity.

Abstract: Schizophrenia, a chronic mental illness, requires long-term treatment with antipsychotics, where adherence is crucial for favorable clinical and economic outcomes. Adherence, however, is a multifaceted concept, not fully captured by a single measure.

Abstract: Objective: To describe the long-term efficacy of esketamine nasal spray (ESK) in adult patients (aged 18-64 years) with treatment-resistant depression (TRD) dosed according to US prescribing information, including an evaluation of early (day 8) and delayed (week 8) responders.

Abstract: Objective: To describe the long-term safety and efficacy of flexibly dosed esketamine nasal spray (ESK) in patients with treatment-resistant depression (TRD) from SUSTAIN-3 (NCT02782104).

Abstract: Background: Long-term safety, tolerability, and durability of therapeutic effect are important aspects of antipsychotic treatment.

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder (BD).

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder (BD).

Tardive dyskinesia (TD), which affects over 500,000 people in the United States (US), is an involuntary movement disorder associated with dopamine-receptor antagonists–most commonly antipsychotic drugs.

Abstract: Background: The IMPACT-TD scale is a newly developed clinical tool to assess the multidimensional impact of tardive dyskinesia (TD) on patients’ quality of life (QoL).

Abstract: Introduction: Obligate mirror alternating hemiprosopometamorphopsia has not heretofore been described. Such a case is presented.

Abstract: Anhedonia is a core feature of major depressive disorder (MDD). However, little is known about its related symptom burden and its impact on patients’ clinical trajectory.

Abstract: LY03010 (paliperidone palmitate) is in development as a pharmaceutical equivalent drug product to the listed drug (LD), INVEGA SUSTENNA® for schizophrenia and schizoaffective disorders with an alternative initial dosing regimen (IDR).

Abstract: The patient is an 81-year-old female with a past medical history of dementia who presented to the hospital for a mechanical fall.

Abstract: Introduction: Iclepertin (BI 425809), a glycine transporter-1 inhibitor, has improved cognitive impairment associated with schizophrenia (CIAS) in Phase II trials, with Phase III trials underway.

Abstract: Depression is a debilitating disorder, and it is expected to overtake cardiac illnesses as the top source of disease burden in 7 years. It is a psychiatric disorder that is diagnosed by using the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5).

Abstract: Background: Psychiatric nurses play a key role in schizophrenia treatment; their perceptions of long-acting injectable antipsychotics (LAIs) vary.

Bipolar disorder (BD) is a serious mental illness and a notoriously challenging disease for healthcare professionals to accurately diagnose and manage.

Abstract: Introduction: AXS-05 (dextromethorphan-bupropion), a novel, oral, N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, gained approval from the US FDA in August 2022 for treating major depressive disorder (MDD) in adults.

Abstract: BACKGROUND: Real-world evidence of clinical benefits of esketamine nasal spray for treatment-resistant depression (TRD) is limited. This study used health insurance claims data augmented with Patient Health Questionnaire (PHQ-9) scores to address this gap in knowledge.

Abstract: Tardive dyskinesia (TD) is a persistent and potentially debilitating movement disorder associated with antipsychotic exposure.

Abstract: Purpose: To examine real-world incidence of esketamine nasal spray (ESK) treatment-emergent adverse events (TEAEs) of interest (i.e., actively solicited events of sedation, dissociation, and increased blood pressure [BP]) and serious adverse events (SAEs) in the US and determine whether

Abstract: Purpose: Agitation treatment in patients with schizophrenia or bipolar disorder is challenging. Alpha-2 agonist, IGALMI™ DSF (dexmedetomidine sublingual film) reduces norepinephrine.

Abstract: Major Depressive Disorder (MDD) is characterized by depressed mood, anhedonia, and diminished quality of life. The varying severity of MDD symptoms impacts treatment response and patient experiences.

Abstract: Assessment of real-world outcomes associated with different antipsychotics helps inform treatment selection for patients with schizophrenia. This real-world study aimed to compare outcomes of patients with schizophrenia treated with once-monthly paliperidone palmitate (PP1M) vs.

Abstract: Background: Two phase 3 trials evaluating TV-46000 for schizophrenia enrolled patients aged 13–65 years. Adolescents aged 13–18 years and young adults aged 19–21 years who received TV-46000 in these studies are included in this safety analysis.

Abstract: Background: In the phase 3 KINECT®-HD (NCT04102579) study, valbenazine significantly improved chorea versus placebo in adults with Huntington’s disease (HD).

Abstract: Background

Abstract: Background: This analysis used pharmacokinetic (PopPK) modeling to characterize dosing conversions and switching strategies from R064766 (a once-every-2-weeks [q2w] intramuscular long-acting injectable antipsychotic formulation of risperidone microspheres) to TV-46000 (a once-monthly [q

While antipsychotic treatment is essential to achieving and maintaining remission in schizophrenia, conventional antipsychotic treatments are associated with numerous shortcomings, including non-adherence, inadequate response, and/or medication-related adverse events.

Abstract: Objective: To describe characteristics of patients from a prospective observational study evaluating postpartum depression (PPD) care pathways.

Abstract: Abstract Background Neurological complications after covid-19 are well described. TMS plays a role in the treatment of this condition. However, the use of TMS in neurological complications following Covid-19 vaccination are not yet reported in the literature.

Abstract: Introduction: Less than half of patients receiving first-line antidepressant (ADT) treatment for major depressive disorder (MDD) achieve remission. When considering the next treatment strategy, healthcare professionals (HCPs) must assess benefits, risks, and other factors.

Abstract: Once-daily valbenazine is approved for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD).

Abstract: Background: The long-acting injectable aripiprazole lauroxil (AL) initiated using a one-time injection of a NanoCrystal Dispersion formulation of AL (ALNCD) and a 30-mg dose of oral aripiprazole significantly improved symptoms of schizophrenia in a phase 3 study.

Abstract: BACKGROUND: Durability of esketamine clinical benefits for treatment resistant depression (TRD) may correlate with treatment sessions completed and therapy persistence.

Abstract: PTSD is defined as a group of symptoms which include intrusive flashbacks and re-experiences of a traumatic event, avoidance of any trauma related stimuli, negative changes in moods and increased arousal and reactivity to one’s environment.

Abstract: Objective: To examine baseline and disease characteristics of patients with treatment-resistant depression (TRD) who achieved remission at week 8 with quetiapine extended release (QXR) or esketamine nasal spray (ESK) (both with an oral antidepressant) in ESCAPE-TRD (NCT04338321) to iden

Abstract: Our case involves a 64-year-old male with a past psychiatric history of schizoaffective disorder (bipolar type; on clozapine 400mg nightly) and who presented to the hospital for evaluation after a near syncopal episode and generalized weakness in the setting of 3-7 days of decreased ora

Abstract: Background: We and others surmise that clozapine-induced myocarditis may be more common now that Covid-19 virus is among us. Clozapine, Covid, and the mRNA vaccine used to fight the virus can all independently lead to myocarditis, a potentially fatal sequela.

Abstract: STARS-ADHD-Adolescents was a multicenter, single-arm trial conducted at 14 US research sites to evaluate objective attention functioning and ADHD symptoms and impairments after 4 weeks of AKL-T01 treatment in adolescents aged 13-17 years.

Abstract: Since March of 2020, the leukotriene receptor antagonist Montelukast has been recognized by the FDA to cause adverse neuropsychiatric events including rare cases of nightmares and somnambulism.

Abstract: Objective: To describe key characteristics and treatment patterns in patients with unresolved MDD symptoms by leveraging real-world data.

Abstract: Delirium is not a well-known adverse effect of Vivitrol. This report describes a rare case of delirium involving visual hallucinations and grandiose delusions associated with Vivitrol use that resolved after about 72 hours of being stabilized with lorazepam.

Abstract: Background: Physical manifestations of tardive dyskinesia (TD) impact daily activities and present a substantial psychosocial burden. This study was designed to survey differences in perception of TD impact among US-based patients and healthcare professionals (HCPs).

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-related chorea.

Abstract: Background: Valbenazine and deutetrabenazine (vesicular monoamine transporter 2 inhibitors) are approved in the US for treatment of adults with tardive dyskinesia (TD).

Abstract: Treatment-resistant depression can be difficult to identify in the outpatient behavioral health setting due to a lack of clear diagnostic guidelines.

Abstract: Two patients with previous unsuccessful psychiatric treatment under went a neurophysiologic evaluation method that included EEG, QEEG and Loreta brain scans. Each patient's lab data directed counterintuitive medicinal treatment that has been successful for over 15 years.

Abstract: Fentanyl positivity grew by nearly 150% nationally from 2019 to 2022 and is now the most frequently detected drug in those analyzed with substance use disorder.

Abstract: Background: Effective and comprehensive treatment of tardive dyskinesia (TD) requires reducing patients’ abnormal involuntary movements while maintaining their psychiatric stability.

Abstract: Background: The substantial disease burden of schizophrenia may be accompanied by disparities in diagnosis and treatment, such as with the use of second-generation antipsychotics (SGAs) compared to first-generation antipsychotics (FGAs).

Abstract: Background: Social determinants of health (eg, race/ethnicity, resources) impact quality of care for a number of chronic diseases.

Abstract: Background: TV-46000 is a long-acting subcutaneous antipsychotic (LASCA) that combines risperidone and an innovative, copolymer-based drug delivery technology.

Abstract: Background: Major depressive disorder (MDD) is a debilitating disease for which there is an unmet need for rapid-acting treatments. Zuranolone is an investigational oral, once-daily, 14-day treatment for adults with MDD and PPD.

Abstract: Background: Schizophrenia requires long-term treatment with antipsychotics; however, poor adherence to antipsychotic treatment can result in increased healthcare resource utilization, placing a burden on the healthcare system.

Abstract: Background: Low adherence to antipsychotic medication following a hospital discharge among patients with schizophrenia can lead to a higher risk of relapse and greater health care utilization. Using real-world data from a U.S.

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-related chorea.

Abstract: Background: Valbenazine and deutetrabenazine (vesicular monoamine transporter 2 inhibitors) are indicated for treatment of adults with tardive dyskinesia (TD).

Abstract: Background: Although long-acting injectable antipsychotics (LAIs) improve adherence and reduce schizophrenia relapse rates, they remain underutilized in clinical practice.

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-related chorea.

Abstract: Background: Major depressive disorder (MDD) is a debilitating illness in which depressive symptoms may persist after antidepressant treatment. APA guidelines recommend clinicians modify treatment in patients who are non-responders to 4-8 weeks of treatment with the goal of remission.

<p>Abstract: Background: Upon approving esketamine nasal spray (ESK) in conjunction with an oral antidepressant for treatment-resistant depression in adults, the FDA required a Risk Evaluation and Mitigation Strategy (REMS) to mitigate the risks of serious adverse outcomes resulting from se

Abstract: Background: This post hoc analysis of SUSTAIN-2 (NCT02497287), an open-label, long-term safety and efficacy study of esketamine nasal spray (ESK), assessed sustained response (SR) to ESK in combination with an oral antidepressant (OAD) in adults with treatment-resistant depression (TRD)

Abstract: Objective: ESCAPE‑TRD (NCT04338321), a randomized, open-label, rater-blinded, trial demonstrated benefits for esketamine nasal spray (ESK) versus quetiapine extended release (QXR) for acute and maintenance treatment of adult patients, aged 18-64 years, with treatment-resistant depressio

Abstract: Background: Among patients with schizophrenia, nonadherence to oral antipsychotics increases relapse risk. Adherence may be improved with long-acting injectable (LAI) antipsychotics.

Abstract: OBJECTIVES: To evaluate total all-cause healthcare costs among US patients diagnosed with major depressive disorder (MDD) who failed first-line antidepressant treatment (ADT).

Abstract: Background: Treatment with long-acting injectable antipsychotics (LAIs) reduces relapses in schizophrenia; however, best practices for introducing and transitioning patients to LAIs, as well as how to navigate barriers to LAI initiation, vary among clinicians.

Abstract: Background: The phase 3 schizophrenia program for TV-46000, a long-acting subcutaneous antipsychotic (LASCA) formulation of risperidone, included the RISE efficacy study (NCT03503318) and the SHINE long-term safety study (NCT03893825).

Abstract: Background: In 2020, approximately 14.2 million US adults suffered with serious mental illness.

Abstract: Background: Valbenazine is a highly selective vesicular monoamine transporter 2 inhibitor indicated for tardive dyskinesia (TD), a persistent and potentially debilitating movement disorder associated with prolonged antipsychotic exposure.

Abstract: OBJECTIVES: Evaluate clinical and economic outcomes of zuranolone, an investigational drug, versus standard-of-care (SOC) antidepressants in adult patients with major depressive disorder (MDD) to generate suggested value-based willingness-to-pay (WTP) ranges for zuranolone.